The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...
Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care. Circulating tumor DNA, also referred to as ctDNA, are small pieces of DNA that are ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
or on the link below. The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in ...
This work reviews CM-cfDNA methods applied to clinical oncology, emphasizing both machine learning (ML) techniques and mechanistic approaches. The latter integrate biological principles, enabling a ...
Circulating tumor DNA (ctDNA), small pieces of DNA released from dying tumor cells into the bloodstream, can be easily and non-invasively identified and examined through a simple blood test. This ...
The researchers found that within 4 months after blood collection, all 8 participants who scored positively with a multicancer early detection (MCED) test were diagnosed with cancer. HealthDay News — ...
LA JOLLA, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics, a company focused on the development and application of novel DNA methylation technologies to genetic diagnosis, today announced ...
Exact Science’s Michelle Beidelschies, PhD, reveals how a multi-biomarker class multi-cancer early detection test (MCED) blood test can help health systems expand detection across more cancers earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback